Imperial College London and The Francis Crick Institute, London, UK

Research

The Tate lab develops novel chemical biology approaches to enable drug discovery against post-translational modification (PTM) pathways and intractable drug targets, including chemical proteomic target identification, screening technologies, and chemical probe discovery for protein-protein interactions and enzymes modulating PTMs. Recent highlights include the first cell-active activity-based probes (ABPs) for deubiquitinases (DUBs), new tools for analysis and discovery of pathogenic secreted protease activities, and pioneering advances in technology and drug discovery targeting protein lipidation PTM through chemical genetics and proteomics. His lab is also interested in developing new therapeutic modalities including molecular glues and the first examples of antibody-PROTAC conjugates.

Academic Career

Ed Tate holds the GSK Chair in Chemical Biology at Imperial College London, he is a Group Leader at the Francis Crick Institute, and academic founder of Myricx Bio, a biotech company developing his lab’s research toward clinical applications. Following his PhD (2000) with Steve Ley in Cambridge and postdoctoral research in Paris, he was awarded a BBSRC David Phillips Fellowship in 2006 to start his group at Imperial College. He sits on advisory boards of several international research institutes and biotechs, and his research has been recognised by awards and Fellowships, including the 2020 Corday-Morgan Prize and 2022 Cancer Research UK Programme Award. In 2023 he was appointed to the GSK Endowed Chair in Chemical Biology at Imperial College.